Your browser doesn't support javascript.
loading
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power.
Poos, Alexandra M; Schroeder, Cornelia; Jaishankar, Neeraja; Röll, Daniela; Oswald, Marcus; Meiners, Jan; Braun, Delia M; Knotz, Caroline; Frank, Lukas; Gunkel, Manuel; Spilger, Roman; Wollmann, Thomas; Polonski, Adam; Makrypidi-Fraune, Georgia; Fraune, Christoph; Graefen, Markus; Chung, Inn; Stenzel, Alexander; Erfle, Holger; Rohr, Karl; Baniahmad, Aria; Sauter, Guido; Rippe, Karsten; Simon, Ronald; Koenig, Rainer.
Afiliación
  • Poos AM; Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Schroeder C; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Jaishankar N; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
  • Röll D; Institute for Infectious Diseases and Infection Control (IIMK), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Oswald M; Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Meiners J; Institute for Infectious Diseases and Infection Control (IIMK), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Braun DM; Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Knotz C; Institute for Infectious Diseases and Infection Control (IIMK), Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Frank L; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
  • Gunkel M; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Spilger R; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Wollmann T; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Polonski A; VIROQUANT CellNetworks RNAi Screening Facility and Research Group High-Content Analysis of the Cell (HiCell), BioQuant Center, Heidelberg University, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany.
  • Makrypidi-Fraune G; Biomedical Computer Vision Group, BioQuant Center and IPMB, Heidelberg University and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 267, 69120 Heidelberg, Germany.
  • Fraune C; Biomedical Computer Vision Group, BioQuant Center and IPMB, Heidelberg University and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 267, 69120 Heidelberg, Germany.
  • Graefen M; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
  • Chung I; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
  • Stenzel A; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
  • Erfle H; Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Rohr K; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
  • Baniahmad A; Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Sauter G; VIROQUANT CellNetworks RNAi Screening Facility and Research Group High-Content Analysis of the Cell (HiCell), BioQuant Center, Heidelberg University, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany.
  • Rippe K; Biomedical Computer Vision Group, BioQuant Center and IPMB, Heidelberg University and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 267, 69120 Heidelberg, Germany.
  • Simon R; Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Koenig R; Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20251 Hamburg, Germany.
Cancers (Basel) ; 14(5)2022 Mar 01.
Article en En | MEDLINE | ID: mdl-35267575
ABSTRACT
The current risk stratification in prostate cancer (PCa) is frequently insufficient to adequately predict disease development and outcome. One hallmark of cancer is telomere maintenance. For telomere maintenance, PCa cells exclusively employ telomerase, making it essential for this cancer entity. However, TERT, the catalytic protein component of the reverse transcriptase telomerase, itself does not suit as a prognostic marker for prostate cancer as it is rather low expressed. We investigated if, instead of TERT, transcription factors regulating TERT may suit as prognostic markers. To identify transcription factors regulating TERT, we developed and applied a new gene regulatory modeling strategy to a comprehensive transcriptome dataset of 445 primary PCa. Six transcription factors were predicted as TERT regulators, and most prominently, the developmental morphogenic factor PITX1. PITX1 expression positively correlated with telomere staining intensity in PCa tumor samples. Functional assays and chromatin immune-precipitation showed that PITX1 activates TERT expression in PCa cells. Clinically, we observed that PITX1 is an excellent prognostic marker, as concluded from an analysis of more than 15,000 PCa samples. PITX1 expression in tumor samples associated with (i) increased Ki67 expression indicating increased tumor growth, (ii) a worse prognosis, and (iii) correlated with telomere length.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania